As Biotechnology companies, Acasti Pharma Inc. (NASDAQ:ACST) and scPharmaceuticals Inc. (NASDAQ:SCPH) are our subject to compare. And more specifically their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Acasti Pharma Inc. | 1 | 0.00 | N/A | -1.22 | 0.00 |
| scPharmaceuticals Inc. | 4 | 0.00 | N/A | -1.59 | 0.00 |
Table 1 shows the top-line revenue, earnings per share and valuation for Acasti Pharma Inc. and scPharmaceuticals Inc.
Profitability
Table 2 shows us the return on assets, net margins and return on equity of both companies.
| Net Margins | Return on Equity | Return on Assets | |
| Acasti Pharma Inc. | 0.00% | 0% | 0% |
| scPharmaceuticals Inc. | 0.00% | -36.7% | -30.6% |
Analyst Recommendations
Acasti Pharma Inc. and scPharmaceuticals Inc. Ratings and Recommendations are available in the next table.
| Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
| Acasti Pharma Inc. | 0 | 0 | 1 | 3.00 |
| scPharmaceuticals Inc. | 0 | 0 | 0 | 0.00 |
Acasti Pharma Inc.’s upside potential is 262.15% at a $7.75 consensus target price.
Insider & Institutional Ownership
The shares of both Acasti Pharma Inc. and scPharmaceuticals Inc. are owned by institutional investors at 4.02% and 60.3% respectively. About 13.28% of Acasti Pharma Inc.’s share are held by insiders. Comparatively, scPharmaceuticals Inc. has 0.1% of it’s share held by insiders.
Performance
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| Acasti Pharma Inc. | 2.99% | 107.76% | 181.87% | 129.52% | 338.18% | 189.7% |
| scPharmaceuticals Inc. | 10.06% | 79.01% | 80.12% | 54.67% | 25% | 54.26% |
For the past year Acasti Pharma Inc.’s stock price has bigger growth than scPharmaceuticals Inc.
Summary
Acasti Pharma Inc. beats scPharmaceuticals Inc. on 5 of the 7 factors.
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia. Acasti Pharma Inc. was incorporated in 2002 and is based in Laval, Canada.
scPharmaceuticals Inc., biopharmaceutical company, engages in the development and commercialization of transformative pharmaceutical products. The company's under development products are for heart failure and infectious diseases that include Furoscix that is for treatment of worsening or decompensated heart failure outside of the inpatient setting. scPharmaceuticals Inc. formerly known as scPharmaceuticals LLC. and changed its name to scPharmaceuticals Inc. in March 2014. The company was founded 2013 and is based in Burlington, Massachusetts.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
